Event Recap: Machine Learning for Personalized Cancer Care |
On June 5, 2024, Moores welcomed Adam Yala, PhD, who presented “Machine Learning for Personalized Cancer Care.” Co-hosted by Diane Simeone, MD, and J. Silvio Gutkind, PhD, the talk emphasized the vital role of AI in advancing cancer detection and treatment, reflecting Moores' commitment to technological innovation in healthcare.
|
|
|
Moores Dr. Ramez Eskander Served as PI of FDA Approved Treatment for Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma
|
Keytruda has become the sole anti-PD-1 therapy approved by the FDA for use with chemotherapy in adult patients with primary advanced or recurrent endometrial carcinoma, irrespective of their mismatch repair status.
|
Ryan Fernandez New Program Manager for EDI at Moores
|
Ryan joins Moores from UC San Diego, where he served on the senior team for Early Academic Outreach Program (EAOP) with CREATE (Center for Research on Educational Equity, Assessment, and Teaching Excellence). With over 10 years of experience, Ryan specializes in managing and evaluating educational outreach and addressing barriers for first-generation students in various school districts. Welcome Ryan!
|
Moores Scientist Named Pew-Stewart Scholar for Cancer Research
|
Moores Member Shiri Gur-Cohen, PhD is one of only five honorees to be named a Pew-Stewart Scholar for Cancer Research. This award honors early career scientists whose innovative research accelerates discoveries to eradicate cancer. Dr. Gur-Cohen is the first Pew-Stewart scholar from UC San Diego, and she is committed to galvanizing a new generation of scientists and physicians dedicated to innovative research and collaboration.
|
|
|
July 1, 2024 | 3:00 p.m. to 4:00 p.m.
Duane Roth Auditorium (Sanford Consortium for Regenerative Medicine) and Zoom
|
July 10, 2024 | 12:00 p.m. to 1:00 p.m.
Moores Comer Commons and Zoom
|
Distinguished Scientist: Director’s Seminar Series
|
Thomas F. Gajewski, MD, PhD
|
July 11, 2024 | 4:00 p.m. to 5:00 p.m.
Goldberg Auditorium and Zoom
| July 12, 2024 | 12:00 p.m. to 1:00 p.m.
Moores Comer Commons and Zoom
|
July 17, 2024 | 12:00 p.m. to 1:00 p.m.
Moores Comer Commons and Zoom
|
September 19, 2024 | 8:30 a.m. to 6:30 p.m.
Duane Roth Auditorium (Sanford Consortium for Regenerative Medicine)
|
|
|
UC San Diego Learning Health System (LHS) Embedded Scientist Training and Research (E-STaR) Center Scholars Program
|
The UC San Diego LHS is funded by the Agency for Healthcare Research and Quality (AHRQ) and the Patient-Centered Outcomes Research Institute (PCORI). The E-STaR program trains researchers in patient-centered outcomes research within learning health systems. Participants gain the unique opportunity to expand their expertise, lead their own research projects, collaborate with top mentors, and engage with community partners to address health disparities.
Program Highlights
|
- Funding up to $45,000/year for 1–2 years
-
Structured training program addressing AHRQ LHS competencies
- Supportive environment fostering professional growth and collaboration
- Co-created, individualized developm
- Opportunities for recognition
|
Application Deadline: July 31, 2024, 11:59 pm PDT
|
|
|
FEATURED FUNDING OPPORTUNITIES |
Department of Defense (DOD), Congressionally Directed Medical Research Programs (CDMRP)
|
The DOD CDMRP Breast Cancer Research Program (BCRP) released program announcements for the following funding opportunities:
Era of Hope Scholar Award
LOI Deadline: July 23, 2024
Application Deadline: August 6, 2024
Breakthrough Award Levels 1 and 2
LOI Deadline: September 12, 2024
Application Deadline: September 26, 2024
Clinical Research Extension Award
LOI Deadline: September 12, 2024
Application Deadline: September 26, 2024
Transformative Breast Cancer Consortium Development Award
LOI Deadline: September 12, 2024
Application Deadline: September 26, 2024
|
|
|
| Targeting patient-derived orthotopic gastric cancers with a fluorescent humanized anti-CEA antibody
|
Annals of Surgical Oncology
|
Pradipta Ghosh, MD (Cancer Biology and Signaling), Marygorret Obonyo, PhD (Cancer Biology and Signaling), Robert M. Hoffman, PhD (Solid Tumor Therapeutics), and Michael Bouvet, MD (Solid Tumor Therapeutics)
|
|
|
| The intratumor microbiome varies by geographical location and anatomical site in head and neck squamous cell carcinoma
|
Current Problems in Cancer
|
Kevin T. Brumund, MD (Moores Member) and Jessica Wang-Rodriguez, MD (Hematologic Malignancies)
|
|
|
| Multifaceted cancer alleviation by cowpea mosaic virus in a bioprinted ovarian cancer peritoneal spheroid model
|
Nicole F. Steinmetz, PhD (Solid Tumor Therapeutics)
|
|
|
CLINICAL TRIALS OFFICE (CTO) |
UCDCC#303: A Phase II Study of Loncastuximab Tesirine and Rituximab (Lonca-R) Followed by DAEPOCHR in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma (UCHMC 2228)
|
PI: Benjamin Heyman, MD
NCT: NCT05600686
|
20863: A Phase II Study of Binimetinib in Combination with Imatinib in Patients with Advanced KIT-Mutant Melanoma
|
PI: Gregory Daniels, MD, PhD
NCT: NCT04598009
|
A051902: A Randomized Phase II Study of CHO(E)P vs CC486CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas
|
PI: Aaron Goodman, MD
NCT: NCT04803201
|
D516AC00003: A Phase II, Open-Label, Single-Arm Study of Osimertinib as Induction Therapy Prior to CRT and Maintenance Osimertinib in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Stage III, Unresectable Non-Small Cell Lung Cancer (NEOLA) |
PI: Lyudmila Bazhenova, MD
NCT: NCT06194448
|
IDE196-002: IDE196 (Darovasertib) in Combination with Crizotinib Versus Investigators Choice of Treatment as Firstline Therapy in HLAA2 Negative Metastatic Uveal Melanoma (DARUM2)
|
PI: Gregory Daniels, MD, PhD
NCT: NCT05987332
|
UCLA GI-09: A Pilot Study of Zimberelimab and Quemliclustat in Combination with Chemotherapy in Patients with Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
|
PI: Gregory Botta, MD, PhD
NCT: NCT05688215
|
|
|
COMMUNITY OUTREACH AND ENGAGEMENT |
Health Fair at the Mexican Consulate in San Diego |
COE represented Moores at this month's health fair at the Mexican Consulate, providing cancer prevention education and resources to over 30 members of the catchment area.
|
|
|
|
